Parmax Pharma reported a sharp 57% decline in revenue to Rs 12.11 crore for FY26, with net losses widening to Rs 4.16 crore. The company faces significant regulatory scrutiny after statutory auditors flagged violations regarding deposit acceptance, investment holding practices, and internal audit failures. Management has attributed these issues to procedural lapses and is implementing corrective measures as it seeks to stabilize operations.
Parmax Pharma FY26 Financials and Auditor Qualifications
Revenue for FY26 stood at Rs 12.11 crore, down from Rs 28.20 crore in FY25. The net loss widened significantly to Rs 4.16 crore from Rs 2.09 crore in the previous year.
Reader Takeaway: Revenue dropped by over 57% while auditor qualifications highlight critical compliance lapses in governance and financial controls.
What just happened
Parmax Pharma has released its financial results for the year ended March 31, 2026, revealing a difficult fiscal year characterized by falling revenue and rising losses. Alongside the financials, the company’s statutory auditors issued three formal qualifications concerning the company’s adherence to the Companies Act, 2013.
Why this matters
The auditor qualifications point to significant internal control issues. Specifically, the company accepted deposits that violated regulatory provisions, held mutual fund investments in the name of the Managing Director instead of the company, and failed to conduct a mandatory internal audit. While management has characterized these as procedural errors and has begun corrective actions, these lapses represent risks to corporate governance and regulatory compliance.
Business and Operational Context
The 57.06% decline in top-line performance was attributed by the management to macro-economic headwinds and a significant reduction in operational activity. Consequently, no dividends have been recommended by the Board due to the absence of operating profits.
Corporate Developments
To prepare for potential future funding or expansion, the company increased its authorized share capital from Rs 6 crore to Rs 10 crore in June 2026. Furthermore, the company has proposed the appointment of four new directors—Dhiren Chandulal Shah, Sunil Chinubhai Shah, Anjana Paresh Shah, and Ashish Atmaram Shah—pending shareholder approval at the next Annual General Meeting.
What to track next
Investors should focus on the company's progress in rectifying the auditor-flagged violations. Updates on the repayment of unauthorized deposits and the successful re-registration of assets into the company's name will be critical indicators of improving internal controls and financial discipline.